Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) and US pharma giant Merck & Co (NYSE: MRK) have announced that Lynparza (olaparib) has been approved in the European Union (EU) for germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
Between five and seven per cent of patients with metastatic pancreatic cancer have a germline BRCA mutation.
The approval by the European Commission was based on results from the Phase III POLO trial, which were published in The New England Journal of Medicine. It follows the recommendation for approval by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze